This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-15. Anything still debated is marked as such rather than presented as settled.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease. Copper histidinate is a copper replacement therapy given by subcutaneous injection. The most common side effects include infections, respiratory problems, seizures, vomiting, fever, anemia and injection site reactions. Copper histidinate was approved for medical use in the United States in January 2026.
==== On Unnatural Amino Acids ==== Pd-mediated Sonogashira, Heck, and Suzuki-Miyaura cross-coupling reactions have been applied widely to modify peptides and proteins, where diverse Pd reagents have been developed for the application in aqueous solutions. Those reactions require the protein or peptide substrate bearing unnatural functional groups such as alkyne, aryl halides, and aryl boronic acids, which can be achieved through genetic code expansion or post-translational modifications.
He graduated in 1902 and was promoted to second-lieutenant on 1 January 1902 at an official ceremony in the Tsar's Palace. He was also a commander in the 3rd Reserve Regiment of the 2nd Infantry Thracian Division in Peshtera, then moved to Pazardzhik. There, he was promoted to lieutenant in 1905 and then commander.
=== 1960s === 1960: Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones" along with Roger Guillemin and Andrew V. Schally who received it "for their discoveries concerning the peptide hormone production of the brain". 1962: Katherine Johnson performed the calculations for the NASA orbital mission, launching John Glenn as the first person into orbit and returning them safely. 1963: Maria Goeppert Mayer became the first American woman to receive a Nobel Prize in Physics; she shared the prize with J. Hans D. Jensen "for their discoveries concerning nuclear shell structure” and Eugene Paul Wigner "for his contributions to the theory of the atomic nucleus and the elementary particles, particularly through the discovery and application of fundamental symmetry principles". She was born in Poland, but became a U.S. citizen in 1933. 1965: Sister Mary Kenneth Keller became the first American woman to earn a Ph.D. in Computer Science. Her thesis was titled "Inductive Inference on Computer Generated Patterns."
for the 2D (linear) ion trap were also given in literature. There are at least two postulates about the nature of the DC component. The first, of which has been attributed to Ding, assumes for the DIT that the DC component, U depends on not only the mid-level of the AC voltages, V1and V2, but also the duty cycle, d of the waveform:
Sources: en.wikipedia.org
Yet the symbiosis raised a century-long puzzle: if multiple fungi adopted algal partners independently, the "lichen condition" might be polyphyletic. This question of how many times lichenization evolved remained speculative until the advent of molecular phylogenetics. Early lichenologists such as Walter Watson warned that symbiosis can so remodel a fungus that its ancestry becomes hard to trace. Modern molecular studies confirm the problem: convergent thallus forms have evolved repeatedly and even been lost again, making ancestry hard to infer.
== Summary table for classes of nuclides, stable and radioactive == Following is a summary table for the list of 986 nuclides with half-lives greater than one hour. A total of 251 nuclides have never been observed to decay, and are classically considered stable. Of these, 90 are believed to be absolutely stable except to proton decay (which has never been observed), while the rest are "observationally stable" and theoretically can undergo radioactive decay with extremely long half-lives. The remaining tabulated radionuclides have half-lives longer than 1 hour, and are well-characterized (see list of nuclides for a complete tabulation). They include 31 nuclides with measured half-lives longer than the estimated age of the universe (13.8 billion years), and another four nuclides with half-lives long enough (> 100 million years) that they are radioactive primordial nuclides, and may be detected on Earth, having survived from their presence in interstellar dust since before the formation of the Solar System, about 4.6 billion years ago. Another 60+ short-lived nuclides can be detected naturally as daughters of longer-lived nuclides or cosmic-ray products. The remaining known nuclides are known solely from artificial nuclear transmutation. Numbers may change slightly in the future as some nuclides now classified as stable are observed to be radioactive with very long half-lives. This is a summary table for the 986 nuclides with half-lives longer than one hour (including those that are stable), given in list of nuclides.
According to the procedure described in the 1975 Aron patent, and the Pharmaceutical Manufacturing Encyclopedia, equimolar amounts of dimethylamine and 2-cyanoguanidine are dissolved in cold toluene to make a concentrated solution, and an equimolar amount of hydrogen chloride is slowly added. The mixture begins to boil, and after cooling, metformin hydrochloride precipitates with a 96% yield. Excess addition of hydrogen chloride results in the formation of the more soluble metformin dichloride salt, a recently reported impurity.
=== Analogues and derivatives === Analogues and derivatives of nicotine are known. These compounds, often structurally similar and sharing affinity for nicotinic acetylcholine receptors, have applications in pharmacology (e.g., smoking cessation), pest control, and neuroscience research (e.g., multiple domain cognitive enhancement, neuroprotection).
=== Assumed regenerative models === Stem cells are thought to mediate repair via five primary mechanisms: 1) providing an anti-inflammatory effect, 2) homing to damaged tissues and recruiting other cells, such as endothelial progenitor cells, that are necessary for tissue growth, 3) supporting tissue remodeling over scar formation, 4) inhibiting apoptosis, and 5) differentiating into bone, cartilage, tendon, and ligament tissue. To further enrich blood supply to the damaged areas, and consequently promote tissue regeneration, platelet-rich plasma could be used in conjunction with stem cell transplantation. The efficacy of some stem cell populations may also be affected by the method of delivery; for instance, to regenerate bone, stem cells are often introduced in a scaffold where they produce the minerals necessary for generation of functional bone. Stem cells have been shown to have low immunogenicity due to the relatively low number of MHC molecules found on their surface. In addition, they have been found to secrete chemokines that alter the immune response and promote tolerance of the new tissue. This allows for allogeneic treatments to be performed without a high rejection risk.
Sources: en.wikipedia.org
On June 13, 2026 (5 days after her 41st birthday), Pansino slammed her jaw into a boat dock attempting to disembark a chartered boat which served as her birthday party venue, breaking her jaw and several teeth and requiring an implanted plate along her chin to re-solidify her jaw. On September 10, 2026, Pansino publicly announced that she had been sober over the previous two months, and had quit taking "unnecessary medications" with advice from her doctor.
Sindone.org – official site of the custodians of the shroud in Turin Professor Creates 3D Image From Shroud The Shroud of Turin Website – Shroud of Turin Education and Research Association, Inc. website Turin Shroud Center of Colorado – research center of John Jackson, a leading member of the STURP team Good Science, Bad Science, and the Shroud of Turin – 2014 NYUAD Chemistry lecture on YouTube Unwrapping the Shroud – 2009 Discovery channel documentary on YouTube Shroud of Turin Evidence – 2008 BBC documentary on YouTube Barrie Schwortz interview – EWTN interview with photographer Barrie Shwortz on YouTube
=== Intramuscular or intravenous injection === Injection of hydroxycobalamin is often used if digestive absorption is impaired, but this course of action may not be necessary with high-dose oral supplements (such as 0.5–1.0 mg or more), because with large quantities of the vitamin taken orally, even the 1% to 5% of free crystalline B12 that is absorbed along the entire intestine by passive diffusion may be sufficient to provide a necessary amount. A person with cobalamin C disease, a rare autosomal, recessive, inheritance disease which results in combined methylmalonic aciduria and homocystinuria), can be treated with intravenous or intramuscular hydroxocobalamin.
=== Inulin === The GFR can be determined by injecting inulin or the inulin analog sinistrin into the blood stream. Since both inulin and sinistrin are neither reabsorbed nor secreted by the kidney after glomerular filtration, their rate of excretion is directly proportional to the rate of filtration of water and solutes across the glomerular filter. Incomplete urine collection is an important source of error in inulin clearance measurement. Using inulin to measure kidney function is the "gold standard" for comparison with other means of estimating glomerular filtration rate. In 2018, the French pharmacovigilance agency withdrew inulin and sinistrin-based products from the market after some patients experienced hypersensitivity reactions including a fatal outcome. Consequently, the contrast agents iohexol and iothalamate have become more popular alternatives to determine GFR and are considered to show sufficient accuracy to determine GFR.
=== Television === Scénarios sur la drogue (2000) – directed by Guillaume Canet and Jean-Christophe Pagnac (episode "Avalanche") Nana (2001) – directed by Édouard Molinaro The Private Life of Samuel Pepys (2003) – directed by Oliver Parker Gossip Girl (2010) – directed by Mark Piznarski and starring Doillon as herself
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.